Literature DB >> 8618852

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.

G Fang1, H Burger, R Grimson, P Tropper, S Nachman, D Mayers, O Weislow, R Moore, C Reyelt, N Hutcheon, D Baker, B Weiser.   

Abstract

To prevent mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission, it is important to identify its determinants. Because HIV-1 RNA levels can be reduced by antiviral therapy, we examined the role of maternal plasma HIV-1 RNA level in mother-to-child transmission. We used quantitative competitive PCR to measure HIV-RNA in 30 infected pregnant women and then followed their infants prospectively; 27% of the women transmitted HIV-1 to their infants and maternal plasma HIV-1 RNA level correlated strikingly with transmission. Eight of the 10 women with the highest HIV-1 RNA levels at delivery (190,400-1,664,100 copies per ml of plasma) transmitted, while none of the 20 women with lower levels (500-155,800 copies per ml) did (P = 0.0002). Statistical analysis of the distribution of HIV-1 RNA loads in these 30 women projected a threshold for mother-to-child transmission in a larger population; the probability of a woman with a viral RNA level of < or = 100,000 copies per ml not transmitting is predicted to be 97%. Examination of serial HIV-1 RNA levels during pregnancy showed that viral load was stable in women who did not initiate or change antiviral therapy. These data identify maternal plasma HIV-1-RNA level as a major determinant of mother-to-child transmission and suggest that quantitation of HIV-1 RNA may predict the risk of transmission.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8618852      PMCID: PMC40304          DOI: 10.1073/pnas.92.26.12100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

Review 1.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

2.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

3.  A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

Authors:  M J Kozal; R W Shafer; M A Winters; D A Katzenstein; T C Merigan
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

4.  Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection.

Authors:  K Luzuriaga; P McQuilken; A Alimenti; M Somasundaran; R Hesselton; J L Sullivan
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

5.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

6.  Features of HIV-1 that could influence maternal-child transmission.

Authors:  S C Kliks; D W Wara; D V Landers; J A Levy
Journal:  JAMA       Date:  1994-08-10       Impact factor: 56.272

7.  Sensitivity, specificity and predictive value of physical examination, culture and other laboratory studies in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection.

Authors:  M W Kline; F B Hollinger; H M Rosenblatt; B Bohannon; C A Kozinetz; W T Shearer
Journal:  Pediatr Infect Dis J       Date:  1993-01       Impact factor: 2.129

8.  Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.

Authors:  P J Boyer; M Dillon; M Navaie; A Deveikis; M Keller; S O'Rourke; Y J Bryson
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

9.  Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype.

Authors:  G Scarlatti; V Hodara; P Rossi; L Muggiasca; A Bucceri; J Albert; E M Fenyö
Journal:  Virology       Date:  1993-12       Impact factor: 3.616

10.  Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction.

Authors:  M A Winters; L B Tan; D A Katzenstein; T C Merigan
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

View more
  28 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

Review 3.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

4.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 5.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

6.  The clinical utility of viral load monitoring in HIV infection: strengths and limitations.

Authors:  E J Erbelding; T C Quinn
Journal:  Genitourin Med       Date:  1996-12

Review 7.  Mechanisms of resistance to HIV infection.

Authors:  W A Paxton; R A Koup
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant.

Authors:  C C Wilson; R C Brown; B T Korber; B M Wilkes; D J Ruhl; D Sakamoto; K Kunstman; K Luzuriaga; I C Hanson; S M Widmayer; A Wiznia; S Clapp; A J Ammann; R A Koup; S M Wolinsky; B D Walker
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.

Authors:  Kerina Duri; Felicity Z Gumbo; Knut I Kristiansen; Nyaradzi E Kurewa; Munyaradzi P Mapingure; Simbarashe Rusakaniko; Mike Z Chirenje; Fredrik Muller; Babill Stray-Pedersen
Journal:  Virol J       Date:  2010-08-02       Impact factor: 4.099

10.  Fetal allostimulation of maternal cells: a potential mechanism for perinatal HIV transmission following obstetrical hemorrhage.

Authors:  Guangwu Wang; Nazanin Izadpanah; Christina M R Kitchen; Helene B Bernstein
Journal:  AIDS Res Hum Retroviruses       Date:  2008-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.